Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment
Fan Mou, Zhiwei Huang, Yu Cheng, Xue Zhao, Xiujia Sun, Huafang Li, Shunying Yu · 2024
Read Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment by Fan Mou, Zhiwei Huang, Yu Cheng, Xue Zhao, Xiujia Sun, Huafang Li, Shunying Yu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11656427.txt.
Description
Fan Mou and six co-authors use computer models of the human body to study what happens when two drugs for mental illness are taken together. The drugs, aripiprazole and risperidone, are often prescribed side by side. How the body handles one of them can shift with a person's gene type for a key liver enzyme, and with liver damage, raising the risk of wrong doses.
The team built detailed models of both drugs and checked them against real blood level data. Their runs showed that adding risperidone changed the handling of the other drug only slightly in most people. For people with mild liver damage, they advise small dose cuts. The cuts grow larger for those whose gene type makes them break the drug down slowly. The paper turns these results into clear dose advice for each group.
Catalog record
| CREATOR | Fan Mou, Zhiwei Huang, Yu Cheng, Xue Zhao, Xiujia Sun, Huafang Li, Shunying Yu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |